Contact Us

Suggested region and language based on your location

    Your current region and language

    GSK First Pharma Company to Certify All Antibiotic Sites to AMR Kitemark

    GSK has become the first pharmaceutical company to achieve the BSI Kitemark™ for AMR at every one of its antibiotic manufacturing sites worldwide.

    London, 19 November 2026 – GSK has become the first pharmaceutical company to achieve the BSI Kitemark™ for Minimized Risk of Antimicrobial Resistance (AMR) at every one of its antibiotic manufacturing sites worldwide. The announcement coincides with World AMR Awareness Week, which runs from 18 to 24 November.

    The Kitemark, developed by BSI with the AMR Industry Alliance (AMRIA), independently verifies that antibiotic manufacturers appropriately control their manufacturing waste streams and minimize the risk of active pharmaceutical ingredients entering the environment. If not appropriately controlled, waste from antibiotic manufacturing can enter the environment and contribute to the development of AMR, which can reduce how effective antibiotics are in treating infections. Certification involves an initial assessment followed by annual surveillance. The certification is aligned with AMRIA’s Antibiotic Manufacturing Standard, published in May 2025, and is increasingly considered by healthcare procurers, investors and customers.

    The World Health Organization (WHO) names AMR as one of the top global public health threats . It already causes over 1 million deaths each year and, without urgent action, by 2050 almost 40 million lives will have been lost.

    GSK is committed to minimising the environmental impact of antibiotic manufacturing, with clear targets to reduce pharmaceuticals in the environment. In 2024, GSK’s Worthing site became the first in the UK to achieve the Kitemark and, with the certification of its final site in November, the company has met its target for all antibiotic manufacturing sites to be certified by the end of 2026.

    The Access to Medicine Foundation’s 2026 AMR Benchmark highlighted GSK as an example of best practice for responsible manufacturing, naming them as one of only three companies reporting 100% compliance with antibiotic discharge limits in receiving waters for all products manufactured both in-house and by its suppliers.

    Dr Manuela Gazzard, President, Regulatory Services, BSI, said: “The World Health Organization names antimicrobial resistance one of the top global public health threats. Tackling it requires action at every stage of the antibiotic supply chain, including how these vital medicines are made. By certifying every one of its antibiotic manufacturing sites, GSK has shown real leadership and set an example for the pharmaceutical sector to follow. Independent assessment gives patients, healthcare systems and the wider public confidence that these sites are controlling their environmental emissions to reduce the risk of AMR and future proof the effectiveness of antibiotics for generations to come.”

    Regis Simard, President, Global Supply Chain, GSK, said: “Achieving BSI Kitemark certification for all of our antibiotic manufacturing sites is a clear demonstration of GSK’s commitment to addressing AMR. As the first pharmaceutical company to reach this milestone, it reflects our dedication to responsible manufacturing and reducing our environmental impact. This isn’t just about meeting rigorous standards; it’s about setting a new benchmark for the industry and ultimately ensuring that patients around the world can continue to rely on the essential medicines they need.”

    For more information on the Kitemark, please visit: BSI Kitemark for Minimized Risk of Antimicrobial Resistance